Welcome to our dedicated page for Cytek Biosciences news (Ticker: CTKB), a resource for investors and traders seeking the latest updates and insights on Cytek Biosciences stock.
Cytek Biosciences, Inc. reports recurring developments in cell analysis instruments, reagents, services, and financial performance. The company uses patented Full Spectrum Profiling™ (FSP®) technology to analyze fluorescence signals in flow cytometry and related cell analysis workflows.
News about Cytek Biosciences commonly covers earnings releases, revenue trends, recurring service and reagent revenue, instrument placements, product platforms such as Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS, Cytek Aurora™ Evo, Cytek Orion™, ESP™ detection technology, and Amnis® and Guava® products, as well as investor conference participation and business outlook updates.
Cytek Biosciences (Nasdaq: CTKB) will participate in Singular Research’s Las Vegas Invitational Conference, held June 14-16, 2026. Cytek management is scheduled to present on Monday, June 15, 2026, at 11:00 a.m. Pacific Time.
A live and archived webcast will be available on the company’s investor website.
Cytek Biosciences (Nasdaq: CTKB) will showcase major spectral flow cytometry innovations at CYTO 2026 in West Palm Beach, June 6–10, 2026. Highlights include the first public debut of the 7-laser Cytek Borealis system and new automation‑ready Cytek Aurora Evo configurations.
Cytek Biosciences (Nasdaq: CTKB) reported Q1 2026 revenue of $44.1 million, up 6% year-over-year, and service revenue of $15.4 million, up 15% year-over-year. GAAP gross profit was $21.3 million with a 48% gross margin. Net loss was $18.9 million.
Recurring revenue was $18.4 million for the quarter and represented 35% of trailing-12-month revenue. Operating expenses rose 13% and the company reaffirmed full-year 2026 revenue guidance of $205M–$212M. Cash and marketable securities totaled $262.2 million as of March 31, 2026.
Cytek Biosciences (Nasdaq: CTKB) will report first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results, business developments and outlook.
Live audio will be available in the Investors section of the company website at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) marks one year of operations at its 8,500-square-foot Singapore facility on March 9, 2026. The site expanded regional manufacturing capacity, reduced delivery times in key APAC markets, added a dedicated service and training center, and strengthened global supply chain resilience while partnering with local research institutes.
Cytek Biosciences (Nasdaq: CTKB) reported Q4 2025 revenue of $62.1M (+8% YoY) and full-year 2025 revenue of $201.5M (+1% YoY). Recurring revenue grew 21% and comprised 34% of 2025 revenue. GAAP gross margin fell to 52% for 2025; adjusted EBITDA was $5.0M for the year. Net loss was $66.5M, reflecting a $33.1M non-cash valuation allowance on deferred tax assets. Installed base reached 3,664 instruments with 630 placements in 2025. Cytek initiated 2026 revenue guidance of $205M–$212M (2%–5% growth).
Cytek Biosciences (Nasdaq: CTKB) will present at the TD Cowen 46th Annual Health Care Conference in Boston on Wednesday, March 4, 2026. Management will take part in a hybrid presentation and fireside chat at 8:10 a.m. PT / 11:10 a.m. ET.
According to the company, a live and archived webcast will be available via the Investors section at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) will report fourth quarter and full year 2025 financial results after market close on Thursday, February 26, 2026.
Management will host a webcast and conference call beginning at 1:30 p.m. Pacific / 4:30 p.m. Eastern to discuss results, business developments, and outlook. Live audio will be available in the Investors section at investors.cytekbio.com.
Cytek Biosciences (Nasdaq: CTKB) announced preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2025. The company expects full-year 2025 revenue of approximately $201 million and Q4 2025 revenue of approximately $62 million, representing Q4 growth of +8% year-over-year and +19% quarter-over-quarter. Management cited strength in Services, Reagents and Asia Pacific instrument revenue and a return to positive instrument growth in EMEA. Results are preliminary and subject to year-end close and audit. Cytek will report audited results and provide 2026 guidance near the end of February 2026 and will present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Cytek Biosciences (Nasdaq: CTKB) was named to TIME’s 2026 America’s Growth Leaders list, compiled with Statista, recognizing top U.S. public companies for five‑year growth, financial stability, and stock performance. The announcement highlights Cytek’s sustained business expansion and its Full Spectrum Profiling™ (FSP®) flow cytometry platform, which is cited in more than 3,200 peer‑reviewed publications. The recognition underscores the company’s mission to expand access to high‑parameter cell analysis and its role in research areas including cancer, cell and gene therapy, vaccines, and emerging disease response.